Medexus patents expiration

1. Rasuvo patents expiration

RASUVO's oppositions filed in EPO
RASUVO Litigations
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8664231 MEDEXUS Concentrated methotrexate solutions
Jun, 2029

(5 years from now)

Drugs and Companies using METHOTREXATE ingredient

Market Authorisation Date: 10 July, 2014

Treatment: Subcutaneous injection of methotrexate


More Information on Dosage

RASUVO family patents

Family Patents

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic